Results 221 to 230 of about 2,911,119 (244)

310 Inhibition of Trk-driven tumors by the pan-Trk inhibitor RXDX-101

European Journal of Cancer, 2014
D. Anderson, M. Ciomei, P. Banfi, S. Cribioli, E. Ardini, A. Galvani, G. Li   +6 more
openaire   +1 more source

Treatment of renal cell carcinoma: Current status and future directions

Ca-A Cancer Journal for Clinicians, 2017
Pedro Coelho Barata, Brian I Rini
exaly  

Identification of [18F]TRACK, a Fluorine-18-Labeled Tropomyosin Receptor Kinase (Trk) Inhibitor for PET Imaging.

Journal of Medicinal Chemistry, 2018
V. Bernard-Gauthier, Andrew V. Mossine, Anne Mahringer, Arturo Aliaga, Justin J Bailey, X. Shao, J. Stauff, Janna Arteaga, P. Sherman, Marilyn Grand'maison, Pierre-Luc Rochon, B. Wängler, C. Wängler, P. Bartenstein, A. Kostikov, D. Kaplan, G. Fricker, P. Rosa-Neto, P. Scott, R. Schirrmacher   +19 more
semanticscholar   +1 more source

Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy-induced amenorrhea

Ca-A Cancer Journal for Clinicians, 2018
Clement Chung
exaly  

An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma

Nature, 2020
Ugur Sahin, Petra Oehm, Mathias Vormehr
exaly  

Lung cancer: New biological insights and recent therapeutic advances

Ca-A Cancer Journal for Clinicians, 2011
Suresh S Ramalingam, Fadlo R Khuri
exaly  

391 LOXO-101, a pan TRK inhibitor, for the treatment of TRK-driven cancers

European Journal of Cancer, 2014
S. Winski, B. Baer, D. Hartley, S. Rhodes, R. Wallace, S. Smith, N. Nanda, L. Kunkle, P. Lee, K. Bouhana   +9 more
openaire   +1 more source

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Nature Reviews Cancer, 2019
Jonathan J Havel, Diego Chowell, Timothy A Chan   +2 more
exaly  

Appraising iniparib, the PARP inhibitor that never was—what must we learn?

Nature Reviews Clinical Oncology, 2013
Joaquin Mateo, Michael Ong, David S P Tan   +2 more
exaly  

A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1).

, 2018
A. Drilon, S. Ou, B. Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J. Lin, V. Zhu, H. R. Kim, T. Kim, M. Ahn, D. Camidge, John K. C. Lim, S. Stopatschinskaja, J. Cui, D. Hyman, R. Doebele, A. Shaw   +16 more
semanticscholar   +1 more source